Immunovaccine has positive RA preclinical results

Immunovaccine (TSX-V:IMV) has released positive results of a preclinical study testing the efficacy of combining CEL-2000, CEL-SCI Corp.’s (AMEX: CVM) rheumatoid arthritis vaccine antigen, and DepoVax, Immunovaccine’s delivery platform. The study results showed the vaccine combination “considerably lessened the symptoms and slowed the progression of RA” in the animal model with a single dose.  The [...]

Paradigm starts Immunovaccine at buy

Paradigm Capital has initiated coverage of Immunovaccine (TSX-V:IMV) with a “buy” and 12-month price target of $2.50.  The stock closed at $1.30 on Friday. Analyst Claude Camire writes that his target price is based on the sum of the risk-adjusted asset value for the company’s veterinary vaccines of about 75 cents a share and its [...]

Dundee biotech outlook sees ‘ample room for upside’

While we were at the J.P. Morgan Healthcare Conference in San Francisco last week, Dundee Securities issued its latest biotech sector update. On the bright side, analyst David Martin writes that there are signs Biovail, Angiotech and QLT stocks are bouncing back – supported by new strategies and new products in development for each company. [...]